Dr. Gandara on the Utility of TMB in NSCLC
David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.
Related Articles
FDA Fast Track Designation Granted to LYT-200 in Recurrent/Metastatic HNSCC
The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.
Improved Molecular Classification Drives Tailored Treatment Approaches in Endometrial Cancer
Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
The New Frontier With Integrative Oncology: Shooting for the Stars
Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center…
Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in Relapsed/Refractory NHL
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence
Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.
Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL
A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.
FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma
The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple…
Increasingly Targeted ADCs Drive NSCLC Treatment Innovations
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.
A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.